miRNAs in Uremic Cardiomyopathy: A Comprehensive Review.
D'Agostino M, Mauro D, Zicarelli M, Carullo N, Greco M, Andreucci M, Coppolino G, Bolignano D.
Int J Mol Sci. 2023 Mar 12;24(6):5425. doi: 10.3390/ijms24065425.
Implications of uremic cardiomyopathy for the practicing clinician: an educational review.
Hiraiwa H, Kasugai D, Okumura T, Murohara T.
Heart Fail Rev. 2023 Sep;28(5):1129-1139. doi: 10.1007/s10741-023-10318-1. Epub 2023 May 12.
Paracrine Factors in Uremic Cardiomyopathy.
Sucharov CC.
JACC Basic Transl Sci. 2020 Feb 24;5(2):167-168. doi: 10.1016/j.jacbts.2020.01.005. eCollection 2020 Feb.
Uremic cardiomyopathy: an underdiagnosed disease.
Alhaj E, Alhaj N, Rahman I, Niazi TO, Berkowitz R, Klapholz M.
Congest Heart Fail. 2013 Jul-Aug;19(4):E40-5. doi: 10.1111/chf.12030. Epub 2013 Apr 25.
The Redox-Sensitive Na/K-ATPase Signaling in Uremic Cardiomyopathy.
Liu J, Nie Y, Chaudhry M, Bai F, Chuang J, Sodhi K, Shapiro JI.
Int J Mol Sci. 2020 Feb 13;21(4):1256. doi: 10.3390/ijms21041256.
Uremic Cardiomyopathy: A New Piece in the Chronic Kidney Disease-Mineral and Bone Disorder Puzzle.
de Albuquerque Suassuna PG, Sanders-Pinheiro H, de Paula RB.
Front Med (Lausanne). 2018 Jul 24;5:206. doi: 10.3389/fmed.2018.00206. eCollection 2018.
Hemodialysis-induced cardiovascular disease.
Ahmadmehrabi S, Tang WHW.
Semin Dial. 2018 May;31(3):258-267. doi: 10.1111/sdi.12694. Epub 2018 Apr 6.
T(1) and T(2) Mapping in Uremic Cardiomyopathy: An Update.
Arcari L, Camastra G, Ciolina F, Danti M, Cacciotti L.
Card Fail Rev. 2022 Jan 18;8:e02. doi: 10.15420/cfr.2021.19. eCollection 2022 Jan.
Cardiac Metabolism in Heart Failure and Implications for Uremic Cardiomyopathy.
Nguyen TD, Schulze PC.
Circ Res. 2023 Apr 14;132(8):1034-1049. doi: 10.1161/CIRCRESAHA.123.321759. Epub 2023 Apr 13.
Uremic cardiomyopathy and insulin resistance: a critical role for akt?
Semple D, Smith K, Bhandari S, Seymour AM.
J Am Soc Nephrol. 2011 Feb;22(2):207-15. doi: 10.1681/ASN.2009090900. Epub 2010 Jul 15.
